摘要
目的:分析伴有或不伴有膀胱过度活动症(OAB)的良性前列腺增生(BPH)患者尿液前列腺素E2(PGE2)的浓度,确定PGE2是否与BPH继发的OAB相关。方法:86例因下尿路症状(LUTS)就诊的BPH患者根据OAB症状评分(OABSS)分为OAB组和非OAB组。同时选取34例无LUTS的50岁以上男性为对照组。检测这些研究对象的尿液PGE2浓度,并检测BPH患者的残余尿、最大尿流率、前列腺体积和前列腺特异性抗原,记录国际前列腺症状评分(IPSS)和OABSS评分。OAB组给予口服坦索罗辛(0.2mg,1次/d)和酒石酸托特罗定(2mg,2次/d),非OAB组只给予坦索罗辛(0.2mg,1次/d)治疗。PGE2浓度除以尿肌酐浓度为标准化的尿PGE2值。结果:对照组PGE2浓度均明显小于OAB组和非OAB组(P均<0.05);OAB组PGE2浓度高于非OAB组(P<0.05)。经过12周治疗后,OAB组PGE2浓度随着OAB症状的改善明显下降(P<0.05),而非OAB组PGE2浓度无明显变化(P>0.05)。相关性分析显示OAB组的IPSS储尿期评分、OABSS评分都和PGE2浓度无关(P均>0.05)。结论:伴有OAB症的BPH患者尿液PGE2的浓度明显高于正常者和不伴有OAB的BPH患者,并随着OAB的改善而下降。尿PGE2可作为BPH患者OAB存在与否的生物标志。
Objective： To measure the levels of urinary prostaglandins E2 （PGE2） in benign prostatic hyperplasia （BPH） pa- tients with or without overactive bladder （OAB） symptoms and determine whether urinary PGE2 can serve as a biomarker for BPH-re- lated OAB. Methods ： This study included 86 BPH patients and 34 male control subjects without lower urinary tract symptoms. Based on the OAB symptom scores （OABSS） , the BPH cases were classified as BPH/OAB （n =49） and BPH/non-OAB （n = 37） to be treated orally with tamsulosin alone and tamsulosin ＋ toherodine-tartrate, respectively, for 12 weeks. We measured the urinary PGE2 levels of all the subjects by ELISA before and after medication, the total PGE2 level normalized to the concentration of the urinary cre- atinine （PGE2/Cr）. We also obtained the residual urine volume, Qmax, prostate volume, PSA level, IPSS and OABSS of the BPH patients, and compared them among different groups. Results ： The baseline PGE2/Cr level was significantly lower in the control thanin the BPH/OAB and BPH/non-OAB groups （ both P 〈 O. 05 ）, and higher in the BPH/OAB than in the BPH/non-OAB patients （ P 〈0.05）. After 12 weeks treatment, the urinary PGE2/Cr level was remarkably decreased with relief of the OAB symptoms in the BPH/OAB patients （P 〈 O. 05 ）, but not in the BPH/non-OAB group （P 〉 0.05）. The concentration of PGE2 was not correlated with the IPSS storage score and OABSS of the BPH/OAB patients （P 〉 O. 05）. Conclusion ： Patients with BPH/OAB have signi-ficantly higher urinary PGE2/Cr levels than those with BPH/non-OAB and normal controls, which tend to decrease with the alleviation of OAB symptoms. Our findings suggest that urinary PGE2 can be a potential biomarker for BPH/OAB. Natl J Androl, 2014, 20 （3） ： 244 -248
出处
《中华男科学杂志》
CAS
CSCD
2014年第3期244-248,共5页
National Journal of Andrology
关键词
前列腺素E2
良性前列腺增生
膀胱过度活动症
prostaglandins E2
benign prostatic hyperplasia
overactive bladder symptoms
